

MONDAY 10 NOVEMBER			
Registration from 11.00			
12.00 - 13.00 LUNCH			
13.00	13.15	Anna Winge-Main	Welcome address: Setting the Stage: Nordic Light on Melanoma
RETHINKING MELANOMA TREATMENT			
Moderators: Trude Robsahm, Eva Ellebæk, Anna Winge-Main & Truls Ryder			
13.15	13.45	Christian Blank	“Less Is More – Smarter, Not Harder, in Melanoma Treatment”
13.45	14.15	Tamar Nijsten	“Numbers That Matter: Epidemiology in the Clinic”
14.15	14.30	PANEL	Quickfire Discussion
14.30 - 15.00 BREAK			
RETHINKING MELANOMA TREATMENT cont.			
Moderators: Trude Robsahm, Eva Ellebæk, Anna Winge-Main & Truls Ryder			
15.00	15.30	John Paoli	“Skin Deep Insights – a Dermatologists WOW Perspective”
15.30	16.00	Alexander C.J. van Akkooi	“Cutting Edges: Surgical Perspectives on Melanoma”
Abstracts		Epidemiology & Dermatology	
16.00	16.10	Jose Hernán Alfonso	Occupation and cutaneous melanoma: a 60-year cohort study of 22.8 million people in five Nordic countries
16.10	16.15	Yodit Girmay	Recent melanoma incidence trend in Sweden and the effect of immigration
16.15	16.20	Anastasia Giorcelli	Recurrence After Diagnosis of Primary Cutaneous Melanoma; Population-based Risk Prediction
16.20	16.30	Gustav Gede Nervil	Teledermoscopic triage of melanoma-suspicious lesions with multiple assessors: Safe but impractical?
16.30	17.00	PANEL	Crossfire: Multidisciplinary Melanoma Perspectives
18.00 “Rorbua Get Together: Arctic Strings and Nordic Bites” (Rorbua Pub, Samuel Arnesens gate 12, 9008 Tromsø)			

TUESDAY 11 NOVEMBER			
IMMUNOTHERAPY			
Moderators: Marco Donia & Marta Nyakas			
9.00	9.30	Jessica C. Hassel	“Immunotherapy Today and Tomorrow – the 2025 Perspectives”
9.30	10.00	Marco Donia	“Unlocking Immunity – TIL Therapy in Focus”
Abstracts		Immune Therapy	
10.00	10.10	Hildur Helgadóttir	Real-World Evaluation of Two Dosing Regimens, NIVO3+IPI1 or NIVO1+IPI3 in Patients with Advanced Melanoma

10.10	10.15	Henrik Jespersen	Grand SLAM: A Prospective Randomised Multicentre Study of Shortened versus Standard Duration Adjuvant Immune Checkpoint Inhibition (ICI) for Stage IIB-C, III and IV Cutaneous Melanoma (CM)
10.15	10.20	Kjersti Tefre Davidsen	Predictive markers of response to immunotherapy in melanoma using clinical trial data
10.20	10.30	Astrid Berild	Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma (NeoLIPA trial): Rationale, protocol and preliminary results.
10.30 - 11.00 BREAK			
RARE MELANOMAS			
Moderators: Lars Ny & Henrik Jespersen			
11.00	11.30	Paul Nathan	“Rare Frontiers – Uveal and Mucosal Melanoma”
Abstracts		Rare Melanomas	
11.30	11.40	Nils Leitzinger	Uveal, mucosal and acral melanomas: Long-term trends in incidence, survival and treatment in Norway
11.40	11.50	Ida K. Wulff	A nationwide study on Pediatric Melanoma in Denmark: Outcomes, Tumor Characteristics, and Follow-Up Practices Since 2000
11.50	11.55	Vojtech Hanicinec	Path towards Uveal Melanoma transcriptomic Atlas
11.55	12.00	Marcus Nyberg	Head and Neck Mucosal Melanoma: Prognostic Factors and Survival in a Single-Center Experience
12.00 - 13.00 LUNCH			
OPERABLE MELANOMAS			
Moderators: Roger Bagge & Truls Ryder			
13.00	13.15	Truls Ryder	“In the Operating Room – The Oslo Surgical Experience”
13.15	13.45	Alexander C.J. van Akkooi	“Adjuvant Therapy – Current Practice and Future Directions”
13.45	14.10	Roger Olofsson Bagge	“Surgical Strategies in Advanced Melanoma”
Abstracts		Operable Melanoma	
14.10	14.15	Ellen Krabbe	Magnetic seed localization in patients with nodal stage III melanoma and neoadjuvant immunotherapy, a feasibility study
14.15	14.20	Marie Øbo	Peri-operative treatment with tranexamic acid (TXA); prognostic and treatment related impact of the plasmin(ogen) pathway in melanoma
14.20	14.30	Axel Nelson	Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – a Swedish retrospective real-world study (NEO-MEL)
14.30 - 15.00 BREAK			
RESISTANCE AND GENETICS			
Moderators: Hildur Helgadóttir & Anna Winge-Main			
15.00	15.30	Caroline Robert	“Persister Cells – The Hidden Face of Resistance”
15.30	16.00	Karin Wadt	“Genetics – Mapping the Melanoma Genome”
16.00	16.15	Sura Aziz, Katrine Høeg Liland	“Melanoma Under the Microscope – Why Diagnosis Is So Difficult”
Abstracts		Resistance and Genetics	
16.15	16.25	Assia Bassarova	Nevoid and desmoplastic melanoma – two important diagnostic pitfalls
16.25	16.35	Birte B. Lundhaug	Cumulative Cost Analysis of Skin Surveillance versus Cancer Treatment in CDKN2A- or CDK4-related Familial Melanoma: Insights from the EU PREVENTABLE Project
16.35	16.45	Teitur Sævarsson	Cell state dynamics shape the immunogenicity of cutaneous melanomas
16.45	16.55	Veronica Höiom	Polygenic risk scores for melanoma in the Swedish population

16.55	17.05	Eivind Valen Egeland	Gene expression signature and cell populations predict progression in stage III melanoma patients
<i>17.30 - 18.30: Closed meeting; Nordic Melanoma Group (on invitation)</i>			
19.30 Aperitif “Evening Banquet: Together, Inspired by the North” (20.00) (Banquet Hall/Conference Hall, Radisson Blu Hotel Tromsø)			

WEDNESDAY 12 NOVEMBER			
TARGETED THERAPIES Moderators: Kalle Mattila & Marta Nyakas			
9.00	9.30	Reinhard Dummer	“Targeted Therapy – Achievements and Next Challenges”
Abstracts		Signalling and Biomarkers	
9.30	9.35	Anne Huibers	Can immunological phenotype predict response after isolated limb perfusion for patients with in-transit metastasis of melanoma?
9.35	9.40	Anna Fager	Analysis of ctDNA for early detection of relapse in patients with stage III-IV cutaneous melanoma receiving adjuvant PD-1 inhibitor therapy
9.40	9.45	Szabolcs Hetey	Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-Definer) - Metagenomic characterization
9.45	9.50	Francesca Portelli	Improved stratification of risk for progression by incorporating TILs in AJCC staging of stage II cutaneous ulcerated melanomas
9.50	9.55	Silvia Angori	Exploring the effect of SAMHD1 on tumor suppression in cutaneous melanoma
9.55	10.00	Emma Symonds	The effect of uveal melanoma derived extracellular vesicles on hepatocytes in 3D culture
Acta Oncologica Session - case studies Chair: Micaela Hernberg			
10.00	10.10	Cornelia Schuster	Successful Treatment of Stage IV Melanoma with an ALK Inhibitor: A Case Report
10.10	10.20	Valters Vegelis	Unusual Destination: Amelanotic Metastasis of Melanoma in the Palatine Tonsil
10.20	10.30	Jarle Jakobsen	Defying the Odds: A Case Report of Complete Regression of Untreated Metastatic Melanoma
10.30 - 11.00 BREAK			
REAL WORLD DATA AND SIDE EFFECTS Moderators: Henrik Jespersen & Micaela Hernberg			
Abstracts		RWD and Side Effects	
11.00	11.10	Marie Brinch-Møller Weitemeyer	Real-World Patient Selection for Sentinel Lymph Node Biopsy and Associated Survival in Melanoma: Evidence from a Danish Nationwide Cohort
11.10	11.20	Saana Virtanen	Survival after diagnosis of melanoma brain metastases in patients treated with PD-1 inhibitors in Finland
11.20	11.30	Sara Mølgaard Hansen	Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: Evaluation of the MELACARE intervention in a randomised controlled trial
11.30	11.35	Katja Schabet	Real-world data on late progression in patients on BRAF/MEK inhibitor therapy for advanced melanoma
11.35	11.40	Veera Sivonen	Smoking cessation at melanoma diagnosis associated with longer survival – a real-world data study
11.40	11.45	Karolin Isaksson	Validation of data quality in the national population-based Swedish Melanoma Registry
11.45	12.00		Discussion

12.00 - 13.00 LUNCH

TREATMENT BEYOND

Moderators: Inge Marie Svane & Anna Winge-Main

13.00	13.30	Christian Blank	“Overcoming Obstacles – Systemic Therapy After Adjuvant PD-1 Blockade”
13.30	14.00	Inge Marie Svane	“TIL 2.0 – The Next Generation of Cell Therapy”
Abstracts		Treatment Beyond ICI and TT	
14.00	14.10	Lars Ny	Development of locoregional cell therapy using tumor infiltrating lymphocytes for patients with metastatic uveal melanoma
14.10	14.20	Ellen Heurlin	Defining the Role of Radiotherapy in Advanced Melanoma Patients Failing Targeted Therapy
14.20	14.25	Lina Snickars	A retrospective study on treatment experiences of stage IIIB-D/IVM1a melanoma with talimogene laherparepvec (T-VEC) at the Comprehensive Cancer Center, Helsinki University Hospital, Finland
14.25	14.30	Måns Kadefors	Pre-treatment immune profiles in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion

CHALLENGES AND FUTURE PERSPECTIVES

Moderators: Hildur Helgadóttir & Henrik Jespersen

14.30	15.00	Thomas Schopf	“Early Detection – Harnessing AI in Melanoma Diagnostics”
15.00	15.25	PANEL	Burning clinical questions: “Yay” or “Nay”?
15.25	15.30	Anna Winge-Main	Closing remarks and goodbye!

